Women taking popular GLP-1 weight loss drugs like Ozempic and Wegovy had a 30 percent reduced risk of developing breast cancer than people not on the drugs, according to a new study from the University of Pennsylvania Perelman School of Medicine.
The findings build on years of previous studies that tie GLP-1 use to improved outcomes for multiple types of the life-threatening cancer — although past research has also found the drugs have little effect on reducing the risk of obesity-related cancers like breast cancer.
